Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap Down - Should You Sell?

Key Points

• Bio-Rad Laboratories shares gapped down from a previous close of $257.75 to an opening price of $247.05, marking a decline of 4.2%.
• The company reported $2.61 EPS in its last earnings results, with a net margin of 12.50% and a return on equity of 4.01%.
• Bio-Rad operates a market capitalization of $6.72 billion with a healthy balance sheet, showing a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories, Inc. (NYSE:BIO.B - Get Free Report)'s share price gapped down before the market opened on Friday . The stock had previously closed at $257.75, but opened at $247.05. Bio-Rad Laboratories shares last traded at $247.05, with a volume of 200 shares.

Bio-Rad Laboratories Stock Performance

The firm has a market capitalization of $6.72 billion, a price-to-earnings ratio of 21.06 and a beta of 0.78. The company has a fifty day moving average price of $251.00 and a two-hundred day moving average price of $248.67. The company has a current ratio of 5.12, a quick ratio of 3.67 and a debt-to-equity ratio of 0.17.

Bio-Rad Laboratories (NYSE:BIO.B - Get Free Report) last issued its earnings results on Thursday, July 31st. The company reported $2.61 earnings per share for the quarter. Bio-Rad Laboratories had a return on equity of 4.01% and a net margin of 12.50%.

Bio-Rad Laboratories Company Profile

Bio-Rad Laboratories, Inc manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes.